Compare Anheuser-Busch Inbev SA (BUD) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Anheuser-Busch Inbev SA vs 10X Genomics Inc — how do they compare? Anheuser-Busch Inbev SA trades at $79.76 (market cap $153.45B), while 10X Genomics Inc trades at $46.3 (market cap $5.81B). The key difference: Anheuser-Busch Inbev SA is far larger — about 26.4× 10X Genomics Inc's market cap, and Anheuser-Busch Inbev SA pays a 1.7% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| BUD | TXG | |
|---|---|---|
Market Cap | $153.45B | $5.81B |
Sector | Consumer Staples | Health |
52-Week High | $85.09 | $45.80 |
52-Week Low | $57.10 | $11.34 |
Enterprise Value | $214.64B | $5.36B |
Dividend Yield | 1.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BUD trades at $79.33, down 0.35% with bearish technical signals. The company demonstrates solid fundamentals with consistent earnings beats, 11.9% net margin, and improving cash flow. Recent dividend payment of $1.17 and positive analyst sentiment with 57.8% buy ratings support the investment case. Premiumization strategy and digital expansion drive growth amid changing consumer preferences.
Outlook remains positive with $90.08 consensus price target offering 13.5% upside. Key risks include alcohol moderation trends and competitive pressures. Strong balance sheet with declining debt-to-asset ratio to 33.9% provides financial stability. Revenue growth expected to accelerate to $61B in 2026 with expanding margins.
TXG trades at $41.77, down 2.25% today, with a bullish technical setup supported by moving averages. The company shows improving fundamentals with revenue growth to $642.82M in 2025 and narrowing losses, while recent collaborations with Cleveland Clinic and the Proteintech acquisition expand its diagnostic capabilities. Analyst sentiment is mixed with 45% buy ratings but a consensus price target below current levels.
The outlook suggests cautious optimism as TXG demonstrates operational improvement with positive cash flow generation, though profitability remains elusive. Key risks include execution challenges in new ventures and competitive pressures, while upside potential hinges on continued margin expansion and successful integration of recent acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Anheuser-Busch Inbev SA
Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. After the SABMiller acquisition, the company's portfolio now contains five of the top 10 beer brands by sales and 18 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and U.S.-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev and in 2016 acquired SABMiller.
Read more on BUD →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
